Printer Friendly

Pluristem selects fisher for worldwide dispatch.

Pluristem Therapeutics has selected Fisher BioServices as worldwide dispatch distributor of its off-the-shelf PLacental expanded (PLX) cells. Fisher will provide cryogenic storage and distribution of Pluristem's PLX cells for its clinical trials and preclinical sites around the world.

Pluristem is pursuing several indications for which clinical trials and preclinical studies are underway, including intermittent claudication, muscle regeneration, critical limb ischemia, Buerger's disease, and acute radiation syndrome. Other potential indications include the treatment of acute myocardial infarction, lung disease, and bone marrow disease.

"As we expand our roster of clinical trials for our PLX cell therapies for several indications, we needed a reliable leader in cell therapy distribution. Fisher BioServices was the clear choice for us because they are the world's leader in biological materials handling and have supported hundreds of clinical trials," said Zami Aberman, chairman and chief executive officer of Pluristem.

COPYRIGHT 2012 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:INDUSTRY NEWS
Publication:Contract Pharma
Date:Oct 1, 2012
Words:142
Previous Article:Vetter's expands development services.
Next Article:Hovione expands particle design solutions.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters